Tag - MAIA

Developments

MAIA updates survival data from Phase 2 NSCLC trial

MAIA Biotechnology (NYSEA: MAIA) updated preliminary survival data in the Part A safety lead-in of its ongoing THIO-101 phase 2 trial, evaluating THIO in sequential combination with cemiplimab in patients with advanced...

July 10, 2023

Developments

MAIA Biotechnology reports preliminary Phase 2 survival data for NSCLC

MAIA Biotechnology (NYSEA:MAIA) announced preliminary survival data in the Part A safety lead-in of its ongoing Phase 2 trial, THIO-101, evaluating THIO in patients with advanced non-small cell lung cancer (NSCLC). The...

April 20, 2023

Developments

MAIA Biotechnology expands Phase 2 THIO-101 trial to Europe

Regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, have approved implementation of MAIA Biotechnology’s (NASDAQ:MAIA) THIO-101, the company’s Phase 2 clinical trial evaluating its lead...

December 13, 2022

Feature

MAIA telomere-targeting technology aiming at therapy-resistant tumors

MAIA Biotechnology (NYSE American:MAIA) is developing a telomere-targeting immunotherapy, THIO, with a dual mechanism of action, that can be used in sequential combination with existing immune therapies to target cancer.

November 15, 2022

Tag - MAIA

MAIA updates survival data from Phase 2 NSCLC trial

MAIA Biotechnology reports preliminary Phase 2 survival data for NSCLC

MAIA Biotechnology expands Phase 2 THIO-101 trial to Europe

MAIA telomere-targeting technology aiming at therapy-resistant tumors

General

More